Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection
Emma S. Winkler(Washington University in St. Louis), Michael Diamond(Washington University in St. Louis), Robert H. Carnahan(Vanderbilt University Medical Center), Rachel E. Sutton(Vanderbilt University Medical Center), Adrianus C. M. Boon, Jinsheng Yu(Washington University in St. Louis), Hyesun Jang(University of Georgia), Ted M. Ross(Cleveland Clinic), Pavlo Gilchuk(AstraZeneca (Japan)), James Brett Case(Washington University in St. Louis), Ying Huang(Centers for Disease Control and Prevention), James E. Crowe(Vanderbilt University Medical Center), Rita E. Chen(Washington University in St. Louis), Zhenlu Chong(Washington University in St. Louis), Seth J. Zost(Vanderbilt University Medical Center), Matthias Mack(University Hospital Regensburg), Adam L. Bailey(University of Wisconsin–Madison), Richard D. Head(James S. McDonnell Foundation), James D. Allen(Cleveland Clinic Florida), Tamarand L. Darling(Washington University in St. Louis)
Cited by 392
Related Papers
Itaconate Links Inhibition of Succinate Dehydrogenase with Macrophage Metabolic Remodeling and Regulation of Inflammation
|Cell Metabolism|2016|1.5k
Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
|Cell Host & Microbe|2020|1.2k
The continued threat of emerging flaviviruses
|Nature Microbiology|2020|1.1k